JPRN-UMIN000008158已完成2 期
A phase II Study of Bevacizumab plus oral S1 previously treated non-small cell lung Cancer (OSAKA-LCSG1202) - A phase II Study of Bevacizumab plus oral S1 previously treated non-small cell lung Cancer (OSAKA-LCSG1202)
Dept. of Respiratory Medicine, Osaka University Hospital0 个研究点目标入组 30 人开始时间: 2012年7月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
Thirty patients were enrolled. The RR was 6.7% (95%CI 1.8-21.3%), and the disease control rate was 80% (95%CI 62.7-90.5%). Median PFS was 4.8 months (95%CI 2.7-6.4 months), and median OS was 13.8 months (95%CI 8.4 months-not applicable). Patients did not experience any Grade 4 toxicity or treatment-related death. Grade 3 hematologic toxicity (anemia) occurred in one patient (3.3%). The main Grade 3 non-hematologic toxicities were anorexia (10%), infection (10%), and diarrhea (6.7%).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Adjuvant chemotherapy 2.Pneumonia or Pulmonary fibrosis detectable on chest X-rays. History of drug induced interstitial pneumonia. 3.History of severe drug allergy 4.Active synchronous malignancies 5.Patients with pleural effusion, ascites and/or pericardial effusion requiring drainage 6.Severe complication 7.Metastasis to CNS 8.Patients with chest radiation treatment is required to reach the lung irradiation 9.Treated by flucytosine (5-FC) 10.Symptomatic brain metastasis 11.Patients whose participation in the trial is judged to be inappropriate by the attending doctor
研究者
相似试验
已完成
2 期
Bevacizumab (Avastin) therapy in combination with carboplatin and weekly paclitaxel for advanced non-squamous non-small cell lung canceron-squamous Non-small-cell Lung CancerJPRN-UMIN000003566Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital33
已完成
2 期
A phase II study of maintenance bevacizumab plus docetaxel following induction chemotherapy with cisplatin, pemetrexed plus bevacizumab for advanced non-squamous non-small-cell lung cancerAdvanced non-squamous non-small cell lung cancerJPRN-UMIN000014314Hamamatsu Univ. School of Medicine49
已完成
2 期
Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing SarcomaEwing Sarcoma of BoneExtraosseous Ewing SarcomaPeripheral Primitive Neuroectodermal TumorRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorNCT00516295National Cancer Institute (NCI)7
已完成
2 期
JGOG1079Stage IVB, recurrent or persistant cervical cancerJPRN-jRCTs051180157TAKESHIMA Nobuhiro73
撤回
2 期
Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular DegenerationNCT00696592University of Padova80